Stock market wrap: Intel slides, Microsoft bond, crypto falls

Item	Key figure
Microsoft US bond sale (reported)	$25 billion expected
Bambusa Therapeutics IPO (Nasdaq)	$16 per share
Intercontinental Exchange 8-K	Filed Oct. 29; Items 2.02 and 9.01
Bayer Roundup trial	Win in case brought by three women

Late Thursday news flow in the US stock market centered on an after-hours slide in Intel, a large reported bond deal from Microsoft and a new Nasdaq listing. Crypto weakness and a legal win for Bayer rounded out the session.

Key takeaways

• Intel shares fell after hours, according to Investing.com, on chip supply constraints and heavy cash burn.
• Microsoft expects to raise $25 billion in a US bond sale, a source told the outlet.
• Bambusa Therapeutics priced its Nasdaq IPO at $16 per share.
• Intercontinental Exchange filed an earnings-related 8-K on Oct. 29.

Intel drops after hours

Intel shares tumbled in extended trading, according to Investing.com. The report attributes the move to chip supply constraints and a large cash burn. A companion URL for the story points to slower growth and a PC market that remains under pressure.

After-hours moves of this kind often reset expectations for the next regular session. Holders of Intel shares and anyone with exposure to the stock through listed derivatives will watch whether the drop holds at the open. Details of the company’s guidance and cash-flow figures were not available in the material reviewed here.

Microsoft plans $25 billion bond sale

Microsoft expects to raise $25 billion in a US bond sale, according to a source cited by Investing.com. The size makes it a significant investment-grade supply event. Pricing terms, maturities and use of proceeds were not part of the reported summary.

Watch for the final terms once the deal prices, and for how the supply is absorbed by credit markets.

Bambusa Therapeutics prices IPO

Bambusa Therapeutics priced its initial public offering at $16 per share on Nasdaq, Investing.com reported. The pricing sets up first-day trading in the biotech name. Share count and proceeds were not included in the report.

New listings typically do not have listed options at debut, so the first trading session will be the initial read on demand.

Crypto sells off, with Bitcoin and BNB in focus

Investing.com ran explainers on why Bitcoin was dropping and why Binance’s BNB was crashing. The headlines point to broad weakness across major digital assets. The specific drivers and the size of the declines were not in the material available, so readers should consult the full reports.

ICE files earnings 8-K

Intercontinental Exchange, which operates exchanges and clearing houses, filed an 8-K on Oct. 29. The filing carries Item 2.02, results of operations and financial condition, and Item 9.01, financial statements and exhibits. That structure is the standard format for an earnings release. The filing is 518 KB, which indicates substantial exhibits. Exchange operators’ volume and revenue figures are closely followed by derivatives traders, and the exhibits are the place to look for them.

Bayer wins Roundup trial

Bayer won a US trial in which three women alleged that its Roundup weedkiller caused cancer, Investing.com reported. The verdict is a favorable outcome for the company in its long-running US litigation over the product. Further details of the case were not reported in the summary.

Japan’s shoppers under strain

Investing.com also carried a piece on Japan’s beleaguered shoppers, describing them as a worry for convenience stores and the broader economy. It points to pressure on household spending that retailers and policymakers are monitoring.

What to watch

Friday’s open will test the Intel move. Microsoft’s bond pricing and Bambusa’s debut are the next hard data points. Details from ICE’s earnings exhibits are also due for review.